Scientists in the U.S have discovered new targets for the treatment of invasive breast cancer.
A new study, led by Suresh Alahari, PhD, Associate Professor of Biochemistry and Molecular Biology Louisiana State University Health Sciences Center New Orleans, has shown for the first time that a tiny piece of RNA appears to play a major role in the development of invasive breast cancer and identified a gene that appears to inhibit invasive breast cancer.
The LSUHSC researchers are the first to show that miR-27b, a novel microRNA, not only inactivates the ST14 gene which they found suppresses the growth of breast tumour cells, but also that miR-27b stimulates the breast cancer to invade other cells.
They bind to target genes and decrease their function. MicroRNAs may act as oncogenes (a gene that contributes to cancer development) or tumor suppressors.
In this study working with a line of human breast cancer cells, Alahari's team found that aggressively invasive breast tumour cells contain a large quantity of miR-27b molecules, while normal cells do not.
Further analysis revealed that miR-27b increases during cancer progression, in direct proportion to the decrease in function of the ST14 gene.
They found that miR-27b promotes cell growth and cell invasion, suggesting that miR-27b acts as a breast cancer oncogene.
They also found that ST14 inhibits both cell growth and cell invasion, suggesting that ST14 is a breast cancer tumour suppressor gene and that it may also serve as a marker for the early detection of breast cancer.
"We are in the process of confirming these results and these studies will reveal whether ST14 can reduce breast tumour growth in animals. Blocking the miR-27b/ST14 interaction or rescuing ST14 function may be an effective therapeutic approach to advance breast cancer treatment," Alahari said.
The study has been published in the August 21, 2009 issue of the Journal of Biological Chemistry.